Dr. Jeffrey Bluestone
The A. W. and Mary Margaret Clausen Distinguished Professor at the University of California San Francisco and CEO/President Sonoma BioTherapeutics. He is a leading immunologist in the field of T-cell activation, co-stimulation, and immune tolerance research, which has led to the development of multiple pro-tolerogenic immunotherapies and the first checkpoint immunotherapies for cancer treatment. Dr. Bluestone’s research has focused on the critical role of regulatory T cells in autoimmune diseases, organ transplantation and cancer. Dr. Bluestone was the founder and first director of the Immune Tolerance Network, an NIH-funded clinical immunology research program, former UCSF Diabetes Center Director, Executive Vice Chancellor and Provost at UCSF and CEO of the Parker Institute for Cancer Immunotherapy. Dr. Bluestone has authored more than 400 peer-reviewed publications, mentored over 60 graduate students/post-doctoral fellows, and received numerous awards for his work, including election to the American Academy of Arts and Sciences and the National Academy of Medicine.